[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-nerve-fiber-layer-thickness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-nerve-fiber-layer-thickness":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100623423","phase-4-supplementary-kelulut-honey-therapy-in-juvenile-open-angle-glaucoma-effects-on-il-6-rnfl-and-dry-eye-100623423",false,"NCT07396441","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye.","HONEY-JOAG","Inclusion Criteria:\n\nJOAG patients age 15 years old and above until 40 years old at the time of diagnosis Compliant to conventional treatment achieved target intraocular pressure\n\nExclusion Criteria:\n\nPatients with allergy to honey or honey-based products OCT signal less than 6\u002F10 Concurrent retinal diseases and other optic neuropathies Systemic neurodegenerative disease Systemic comorbidities such as diabetes mellitus and autoimmune diseases Patients on other honey-based products for the last 3 months Patient who consumes honey-based products during the study duration of 3 months (monitoring via honey-diary, return of the used sachet during the follow up visits) Patients on anti-oxidants, traditional medications or herbal products for the last 3 months Topical usage of steroids, systemic steroids and non-steroidal anti-inflammatory drugs.\n\nSepsis Compliance less than 75%.","ALL","15 Years","40 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.",[28,29,30,31,32],"Juvenile Open Angle Glaucoma","Dry Eye Disease (DED)","Interleukin 6","Retinal Nerve Fiber Layer Thickness","HbA1c Level","RECRUITING","2026-02-03",{"date":36,"type":37},"2026-02-09","ACTUAL",{"date":39,"type":37},"2026-01-15",{"date":41,"type":22},"2026-06-30",{"name":43,"class":44},"Universiti Sains Malaysia","OTHER",4,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100611077","phase-4-retinal-protective-effects-of-novel-finerenone-in-patients-with-chronic-kidney-disease-100611077","NCT07235891","Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease","Investigating the Impact of Finerenone on Retinal Vascular Dysfunction in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Age: above 18 years\n* Diabetic and non-diabetic non-hemodialysis CKD patients (Stage 2 - Stage 4).\n\nExclusion Criteria:\n\n* Patients on hemodialysis (HD).\n* Serum potassium level \\> 5.5 mEq\u002FL\n* Prior\u002Fplanned ocular interventions (retinal laser treatment, intravitreal injection or vitrectomy).\n* Pregnant and lactating women\n* Malignancy","18 Years",{"count":55,"type":22},40,[25],"Interestingly, A hypothesis-generating analysis was conducted from two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR\u002FDeFineDR), suggesting a potential benefit of finerenone in the delay of progression of non-proliferative diabetic retinopathy (NPDR), independent of baseline HbA1c. Potential benefits of finerenone were also observed in the prevention of required ocular interventions. However, the studies relied on routine ophthalmological examinations done retrospectively, which may have affected data quality and certainly affected quantity. Hence, there is a compelling need to conduct randomized studies with adequate power to detect a potential benefit of finerenone in delaying retinopathy progression, particularly given the lack of alternative options for oral treatment of retinopathy.",[31,59],"Chronic Kidney Disease",[61,62,63],"Retinal dysfunction","Finerenone","Chronic kidney disease","NOT_YET_RECRUITING","2025-11-14",{"date":67,"type":37},"2025-11-19",{"date":69,"type":22},"2025-11-20",{"date":71,"type":22},"2027-03-20",{"name":73,"class":44},"Alexandria University",1]